Smartphone Based-PPG Assessment of REconversion in Persistent Atrial Fibrillation
- Sponsor
- Ziekenhuis Oost-Limburg
- Study ID
- NCT07752940
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Atrial Fibrillation (AF)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Smartphone-based PPG monitoring — DEVICETwice daily smartphone-based PPG monitoring during 7 days before planned admission for electrical cardioversion
Study Details
This study investigates whether a smartphone application that measures heart rhythm using light, a technique known as photoplethysmography or PPG, can accurately detect when the cardiac arrhythmia atrial fibrillation (AF) spontaneously terminates and the heart returns to normal sinus rhythm. This is a prospective, multicentre randomised controlled study conducted at Hospital East Limburg and University Hospitals Leuven. Continuous heart rhythm monitoring with conventional equipment is often not feasible in the home setting because of the high cost and complexity of the equipment. Smartphone-based PPG monitoring offers a practical and affordable alternative. The study will include 200 adult patients with known AF who are scheduled for elective electrical cardioversion. Patient will be randomised to either standard of care (no remote monitoring) or smartphone-based PPG monitoring. During the seven days preceding the procedure, participants in the intervention group will perform PPG and ECG measurements at predefined times using their smartphone and a chest strap. The primary objective is to determine whether this intermittent, app-guided monitoring can detect spontaneous conversion to normal sinus rhythm before the planned cardioversion, thereby preventing unnecessary hospital admissions. In addition, we will evaluate the relationship between symptoms and cardiac rhythm, adherence to and user experience with self-monitoring, and the predictive value of the measured parameters for recurrence of AF or atrial flutter during one year of follow-up.
Key Dates
- First listed
- Aug 7, 2026
- Start date
- Aug 1, 2026
- Status verified
- Jul 2026
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2028
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Active Comparator: Intervention arm (PPG-based monitoring)Twice daily smartphone based PPG assessment of current heart rhythm in the 7 days before planned electrical cardioversion.
- No Intervention: Control armNo additional remote monitoring before planned electrical cardioversion.
Primary Outcome Measure
Cancellation of planned admission for electrical cardioversion. [ Time Frame: From date of randomization until the initial date of planned admission for electrical cardioversion, assessed up to 8 weeks. ]
Central Contacts
- Michiel De Wever, MD+32470059144
- Laurent Pison, MD, PhD
Related Studies
- Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.Recruiting · Cardiovascular Innovation and Research Institute · Glenwood Springs, Colorado
- KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial FibrillationEnrolling By Invitation · Northwestern University · Chicago, Illinois
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)PHASE3 · Recruiting · Anthos Therapeutics, Inc. · Birmingham, Alabama
- Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial FibrillationEARLY_PHASE1 · Recruiting · China National Center for Cardiovascular Diseases · Boston, Massachusetts